A Phase I Dose Finding Study of MB-CART2219.1
NCT07108868
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
CLL
Acute Lymphoblastic Leukemia, Pediatric
Interventions
BIOLOGICAL:
CAR-T cells targeting CD19 and CD22
Sponsor
University Hospital Tuebingen